SBFM (Sunshine Biopharma) Pangali Forward P/E
Sunshine Biopharma (SBFM) revenue dynamics are based on a combination of Canadian generic sales and high-risk developments. The company's forward P/E shift visualizes these fluctuations, where 0.00 describes the current status of the metric. Growth is supported by the creation of a system to combat resistant lung and breast cancer, although drug synthesis and testing have been fully outsourced to external contractors.
Ringkesan rincian data analitis sunshinebiopharma.com (SBFM)
- rega saiki lan proyeksi nilai saham:
- indikator valuasi pasar bisnis:
- informasi kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Sunshine Biopharma|SBFM - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Sunshine Biopharma, Inc.|SBFM - Gunggung kewajiban utang perusahaan|Utang marang nilai buku Sunshine Biopharma Inc.|SBFM - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Sunshine Biopharma|Likuiditas cepet sunshinebiopharma.com
- rincian asil keuangan lan kelipatan valuasi:
SBFM - Asil keuangan resik|Proyeksi bathi mangsa ngarep Sunshine Biopharma|SBFM - Nilai perusahaan marang bathi resik|Pangali Forward P/E Sunshine Biopharma|SBFM - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Sunshine Biopharma Inc.|SBFM - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Sunshine Biopharma|SBFM - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan sunshinebiopharma.com|SBFM - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Sunshine Biopharma
- indikator volume dodolan lan pendapatan:
Analisis dhasar perusahaan:Sunshine Biopharma SBFM
The forward P/E reflects the ratio of the current market value of Sunshine Biopharma (SBFM) to projected net income, allowing investors to assess the extent of the premium paid for future earnings. By analyzing the forward P/E multiple of Sunshine Biopharma (SBFM), one can correlate it with the stability of oncology drug supplies and logistics diversification, which confirms the fundamental reliability of the business and minimizes the risk of capital stagnation.
Analisis perusahaan pesaing
Prakiraan rega marang bathi ONC (BeiGene)|HALO (Halozyme Therapeutics, Inc.) - Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E RVMD (RevMed)|AAPG - Prakiraan rega marang bathi|CGON: Prakiraan rega marang bathi|URGN - Pangali Forward P/E|Bicara Therapeutics (BCAX) - Rega marang bathi mangsa ngarep|Personalis Inc - Pangali mangsa ngarep rega marang bathi|ERAS (Erasca Corp) - Pangali Forward P/E|Rasio prakiraan rega marang bathi Delcath Corp DCTH|Rega marang bathi mangsa ngarep Y-mAbs Therapeutics (YMAB)|Kapitalisasi marang proyeksi bathi aurabiosciences.com|Candel Therapeutics, Inc. - Prakiraan rega marang bathi|Pangali Forward P/E Accuray Inc ARAY|SLS - Rega marang bathi mangsa ngarep|ACTU (Actuate Therapeutics Inc) - Rasio rega marang bathi mangsa ngarep|Citius Oncology, Inc. (CTOR) - Rega marang bathi mangsa ngarep|HURA - Kapitalisasi marang proyeksi bathi|TARA (Protara Therapeutics, Inc.) - Pangali Forward P/E|FATE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E WHWK|Kapitalisasi marang proyeksi bathi tscan.com|Rega marang bathi mangsa ngarep Champions Oncology, Inc. CSBR|XBIT: Rasio rega marang bathi mangsa ngarep|CEL-SCI Corp - Pangali Forward P/E|Rasio prakiraan rega marang bathi OS Therapies Inc.|RADX (Radiopharm Theranostics Limited) - Prakiraan rega marang bathi|Artiva Biotherapeutics - Pangali mangsa ngarep rega marang bathi|ANL (Adlai Nortye Ltd) - Pangali Forward P/E|Rega marang bathi mangsa ngarep VERU|Pangali Forward P/E TPST|Kapitalisasi marang proyeksi bathi xiliotx.com|Rega marang bathi mangsa ngarep Renovaro RENB|Mural Oncology PLC (MURA) - Rasio prakiraan rega marang bathi|KAPA - Rega marang bathi mangsa ngarep|Rasio rega marang bathi sing dikarepake OKUR|GDTC: Pangali Forward P/E|Curis - Pangali mangsa ngarep rega marang bathi|APLM (Apollomics Inc.) - Pangali Forward P/E|Pangali Forward P/E Tharimmune Corporation|Rega marang bathi mangsa ngarep Advanced Biomed Inc (ADVB)|GNPX (genprex.com) - Pangali mangsa ngarep rega marang bathi|Rega marang bathi mangsa ngarep Calidi Biotherapeutics, Inc. CLDI|XBIO - Prakiraan rega marang bathi|Salarius - Pangali Forward P/E|PPBT - Pangali Forward P/E|aoncology.com (AONC) - Rega marang bathi mangsa ngarep|BGNE - Kapitalisasi marang proyeksi bathi|CKPT (Checkpoint Therapeutics, Inc.) - Pangali Forward P/E|Rega marang bathi mangsa ngarep ELEV|Pangali Forward P/E ICAD|IKNA: Rasio rega marang bathi sing dikarepake|Rega marang bathi mangsa ngarep Notable Labs, Ltd. NTBL|VIRX - Prakiraan rega marang bathi|MorphoSys - Pangali Forward P/E|NAYA Biosciences Inc (NAYA) - Prakiraan rega marang bathi|AAPGV: Pangali Forward P/E
